Analysis of the clinical course, complications and causes of mortality at the onset of the primary necrotizing systemic vasculitis

Abstract

BACKGROUND: Primary necrotizing systemic vasculitis is a significant problem of practical healthcare due to a severe progressive clinical course and a high risk of complications, including life-threatening damage.

AIM: To evaluate the features of the clinical course of primary necrotizing systemic vasculitis during the first 3 years of the disease.

MATERIALS AND METHODS: The study included 232 patients with primary necrotizing systemic vasculitis, who were hospitalized in Saint Petersburg clinics from 2010 to 2018. The features of the clinical course, complications, causes of mortality during the first 3 years of the disease were assessed.

RESULTS: The cohort of patients with рrimary necrotizing systemic vasculitis consisted of patients with granulomatosis with polyangiitis (n = 94), microscopic polyangiitis (n = 46), eosinophilic granulomatosis with polyangiitis (n = 69), polyarteritis nodosa (n = 23). The highest values of the Birmingham Vasculitis Activity Score index were noted among patients with granulomatosis with polyangiitis and microscopic polyangiitis (21.4 and 21.5 points, respectively). Patients with microscopic polyangiitis were significantly more likely to develop chronic kidney disease (C3a–C5 stages) compared to other primary necrotizing systemic vasculitis (p < 0.001). We established that the average value of the Vasculitis Damage Index after 36 months of the disease was highest in the group of patients with granulomatosis with polyangiitis (4.7 points) and significantly exceeded the corresponding indicator at the same period of the disease in the group of patients with microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, polyarteritis nodosa (3.8, 2.7 and 3.1 points, respectively).

CONCLUSIONS: The most unfavorable prognosis among primary necrotizing systemic vasculitis during the first 3 years of the disease was noted in patients with granulomatosis with polyangiitis, which is reflected in the high level of the Vasculitis Damage Index that shows the number of irreversible organ lesions.

Keywords

systemic vasculitis associated with antineutrophil cytoplasmic antibodies / granulomatous with polyangiitis / microscopic polyangiitis / eosinophilic granulomatous with polyangiitis / polyarteritis nodosa / complications

References

[1] Klinicheskaya revmatologiya. Rukovodstvo dlya vrachei. Ed. by V.I. Mazurov. 3rd ed. Moscow: E-noto; 2021. 696 p. (In Russ.)

[2] Клиническая ревматология. Руководство для врачей / под ред. В.И. Мазурова. 3-е изд., перераб. и доп. Москва: Е-ното, 2021. 696 с.

[3] Mazurov VI, Lesnyak OM. Revmatologiya. Farmakoterapiya bez oshibok. Rukovodstvo dlya vrachei. Moscow: E-noto; 2017. P. 479–505. (In Russ.)

[4] Мазуров В.И., Лесняк О.М. Ревматология. Фармакотерапия без ошибок. Руководство для врачей. Москва: Е-ното, 2017. С. 479–505.

[5] Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteriitis nodosa, microscopic polyangiitis, Wegener’s granulomatosis and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51(1):92–99. DOI: 10.1002/art.20077

[6] Mahr A., Guillevin L., Poissonnet M., Aymé S. Prevalences of polyarteriitis nodosa, microscopic polyangiitis, Wegener’s granulomatosis and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate // Arthritis Rheum. 2004. Vol. 51, No. 1. P. 92–99. DOI: 10.1002/art.20077

[7] Watts RA, Scott DGI. Epidemiology of vasculitis. Oxford: Oxford University Press; 2008. P. 7–22.

[8] Watts R.A., Scott D.G.I. Epidemiology of vasculitis. Oxford: Oxford University Press, 2008. P. 7–22.

[9] Vasculitis in Clinical Practice. Ed. by R.A Watts, D.G.I. Scott. New York: Springer-Verlag; 2010. P. 71–77.

[10] Vasculitis in Clinical Practice. Ed. by R.A. Watts, D.G.I. Scott. New York: Springer-Verlag, 2010. P. 71–77.

[11] Nasonov EL, Baranov AA, Shilkina NP. Vaskulity i vaskulopatii. Yaroslavl’: Verkhnyaya Volga; 1999. P. 340–347. (In Russ.)

[12] Насонов Е.Л., Баранов А.А., Шилкина Н.П. Васкулиты и васкулопатии. Ярославль: Верхняя Волга, 1999. С. 340–347.

[13] Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 1990;33(8):1135–1136. DOI: 10.1002/art.1780330812

[14] Fries J.F., Hunder G.G., Bloch D.A. et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary // Arthritis Rheum. 1990. Vol. 33, No. 8. P. 1135–1136. DOI: 10.1002/art.1780330812

[15] Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671–678.

[16] Luqmani R.A., Bacon P.A., Moots R.J. et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis // QJM. 1994. Vol. 87, No. 11. P. 671–678.

[17] Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2):371–380. DOI: 10.1002/art.1780400222

[18] Exley A.R., Bacon P.A., Luqmani R.A. et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides // Arthritis Rheum. 1997. Vol. 40, No. 2. P. 371–380. DOI: 10.1002/art.1780400222

[19] Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41:776–784. DOI: 10.1016/s0272-6386(03)00025-8

[20] Booth A.D., Almond M.K., Burns A. et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study // Am. J. Kidney Dis. 2003. Vol. 41. P. 776–784. DOI: 10.1016/s0272-6386(03)00025-8

[21] Drooger JC, Dees A, Swaak AJG. ANCA-positive patients: The Influence of PR3 and MPO antibodies on survival rate and the association with clinical and laboratory characteristics. Open Rheumatol J. 2009;3:14–17. DOI: 10.2174/1874312900903010014

[22] Drooger J.C., Dees A., Swaak A.J.G. ANCA-positive patients: The influence of PR3 and MPO antibodies on survival rate and the association with clinical and laboratory characteristics // Open Rheumatol. J. 2009. Vol. 3. P. 14–17. DOI: 10.2174/1874312900903010014

RIGHTS & PERMISSIONS

Eco-Vector